Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Fibrodysplasia Ossificans Progressiva clinical trials
Every US clinical trial registered for Fibrodysplasia Ossificans Progressiva — phase mix, recruiting status, and the sponsors running them, straight from the NIH ClinicalTrials.gov registry.
5 US clinical trials · 1 currently recruiting
The research picture
Fibrodysplasia Ossificans Progressiva has 5 registered US clinical trials, 1 of them open to new participants right now — about 20% of the total.
- 1
- recruiting participants now
- 20%
- of trials open to enrollment
- 1
- in Phase 3–4 (later-stage)
- 2
- top sponsor: Clementia Pharmaceuticals
Counts reflect the public ClinicalTrials.gov registry as last mirrored by PlainTrial. Status and phase are reported by each study's sponsor. This is reference information, not medical advice.
Active & Recent Trials
A Study to Document and to Further Describe Long-term Safety and Effectiveness of Palovarotene in Participants With Fibrodysplasia Ossificans Progressiva (FOP)
Ipsen
NCT06089616
A Study to Assess the Effectiveness and Safety of 2 Dosage Regimens of Oral Fidrisertib (IPN60130) for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP).
Clementia Pharmaceuticals
NCT05039515
A Study of Andecaliximab in Participants With Fibrodysplasia Ossificans Progressiva (FOP)
Ashibio
NCT06508021
A Study to Assess Safety, Tolerability and Efficacy of Garetosmab Versus Placebo Administered Intravenously (IV) in Adult Participants With Fibrodysplasia Ossificans Progressiva (FOP)
Regeneron Pharmaceuticals
NCT05394116
Study Evaluating the Effect of Food on the Pharmacokinetics of Palovarotene and the Effect of Palovarotene on the Pharmacokinetics of the CYP3A4 Substrate Midazolam in Two Cohorts of Healthy Adult Subjects
Clementia Pharmaceuticals
NCT04829773
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 2 |
| Phase 3 | 1 |
Top Sponsors
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Reading the Fibrodysplasia Ossificans Progressiva Trial Landscape
ClinicalTrials.gov lists 5 US studies indexed under Fibrodysplasia Ossificans Progressiva, and 1 of those are currently open to recruitment — roughly 20% of the total volume on the registry. That ratio is a useful proxy for activity level: a high share of recruiting studies often signals that research interest is current and that new enrollment opportunities are appearing, while a low share typically means the field is dominated by completed or follow-up work where most participant spots have already been filled. These counts reflect the public registry only and include studies at every stage of design, so they should be read as an index of research attention rather than as a measure of treatment availability.
The phase distribution for Fibrodysplasia Ossificans Progressiva shows 1 late-stage studies (Phase 3 and Phase 4 combined) alongside 3 earlier-phase entries (Phase 1 through Phase 2). Phase 1 and Phase 2 studies focus on early safety signals, dosing, and preliminary effect, while Phase 3 studies are typically the larger efficacy and safety trials submitted toward regulatory review, and Phase 4 studies follow approved interventions in real-world use. A condition weighted toward later phases often reflects a mature research pipeline with several interventions already close to or past approval, whereas a heavier early-phase tilt suggests the field is still exploring new mechanisms and candidate approaches.
Top sponsor activity for Fibrodysplasia Ossificans Progressiva is led by Clementia Pharmaceuticals with 2 indexed trials, alongside 3 other organizations in the top contributor list. The list on this page surfaces up to 5 of the most relevant recent and active entries, ordered with recruiting studies first so practical options are visible. All figures are derived from the public ClinicalTrials.gov dataset maintained by the National Library of Medicine and are reproduced here for reference. Inclusion of a trial, sponsor, or intervention on this page is neither an endorsement nor a recommendation — eligibility, protocol changes, and site-level status can shift frequently, so always verify current details on ClinicalTrials.gov and consult a qualified healthcare provider before acting on anything you see here.
Frequently Asked Questions
How many clinical trials are there for Fibrodysplasia Ossificans Progressiva?
PlainTrial tracks 5 US clinical trials for Fibrodysplasia Ossificans Progressiva, of which 1 are currently recruiting participants. Data sourced from ClinicalTrials.gov.
How do I find a recruiting trial for Fibrodysplasia Ossificans Progressiva?
Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.
Is this data current?
Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.
Related
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.
Read our methodology — how this data is sourced, computed, and verified.
Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.